Blueprint Medicine Gains US Approval For First Drug, Precision Medicine Ayvakit
Targets Mutation In GIST tumors
The FDA has granted full approval to the drug based on Phase I efficacy data and safety studies, reflecting lack of existing treatment options
You may also be interested in...
Chief operating officer Christina Rossi talked to Scrip about the company’s new blockbuster-sized commercial opportunity for Ayvakit and the company’s next phase: financial sustainability.
The company’s rollout plans for Ayvakit appear similar to its approach when it marketed the drug for GIST, with an education plan to help boost sales.
Qinlock (ripretinib), approved as the US FDA rejected Blueprint Medicines’ Ayvakit (avapritinib) in the same indication, is priced on par with the rival drug cleared in January for a narrower GIST use.